Literature DB >> 11132219

Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.

C R Morris1, F A Kuypers, S Larkin, E P Vichinsky, L A Styles.   

Abstract

PURPOSE: Our objective was to evaluate L-arginine and nitric oxide metabolite (NOx) levels in children with sickle cell disease (SCD) at steady-state and during vaso-occlusive crisis (VOC). Because alterations in nitric oxide production may have an important role in the pathophysiology of SCD, our second aim was to determine if a relationship exists between these levels and vaso-occlusive crisis (VOC). PATIENTS AND METHODS: Plasma L-arginine and serum NOx levels were examined in 36 patients with SCD with 39 episodes of VOC and 10 children with SCD at steady-state. Daily levels were obtained in children requiring hospitalization.
RESULTS: Steady-state L-arginine levels were normal in children with SCD. L-arginine levels were low, however, in children with VOC (37.4 +/- 2.7 vs. 53.6 +/- 4.6 micromol/L; P = 0.008) but returned to baseline during hospitalization. In contrast, NOx levels were normal at presentation but decreased during hospitalization for both patients with VOC and patients with acute chest syndrome (ACS) (21.1 +/- 2.0, 17.4 +/- 2.4, and 12.3 +/- 1.6 micromol/L, respectively; P < 0.05). In the patients with VOC who had ACS develop, L-arginine decreased to the lowest levels at the time of the ACS diagnosis, correlating with decreasing NOx levels.
CONCLUSION: These data suggest that there may be a relationship between the L-arginine-nitric oxide pathway and vaso-occlusion in SCD. Low arginine levels during VOC could reflect a state of acute substrate depletion that results in a decrease in nitric oxide production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11132219     DOI: 10.1097/00043426-200011000-00009

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  53 in total

1.  Overactive bladder in adults with sickle cell disease.

Authors:  Uzoma A Anele; Belinda F Morrison; Marvin E Reid; Wendy Madden; Shara Foster; Arthur L Burnett
Journal:  Neurourol Urodyn       Date:  2015-04-14       Impact factor: 2.696

2.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

3.  Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.

Authors:  Charles T Quinn; Elizabeth P Shull; Naveed Ahmad; Nancy J Lee; Zora R Rogers; George R Buchanan
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

4.  Cerebrovascular disease associated with sickle cell pulmonary hypertension.

Authors:  Gregory J Kato; Matthew Hsieh; Roberto Machado; James Taylor; Jane Little; John A Butman; Tanya Lehky; John Tisdale; Mark T Gladwin
Journal:  Am J Hematol       Date:  2006-07       Impact factor: 10.047

5.  Endothelial function in patients with sickle cell anemia during and after sickle cell crises.

Authors:  Arnon Blum; Shay Yeganeh; Aviva Peleg; Fina Vigder; Konstantin Kryuger; Ahmed Khatib; Khalid Khazim; Harold Dauerman
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

Review 6.  Redox-dependent impairment of vascular function in sickle cell disease.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2007-08-31       Impact factor: 7.376

Review 7.  Sickle cell disease and nitric oxide: a paradigm shift?

Authors:  A Kyle Mack; Gregory J Kato
Journal:  Int J Biochem Cell Biol       Date:  2006-02-17       Impact factor: 5.085

Review 8.  Targeting novel mechanisms of pain in sickle cell disease.

Authors:  Huy Tran; Mihir Gupta; Kalpna Gupta
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

9.  Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.

Authors:  Jane A Little; Kristine Partovi Hauser; Sabrina E Martyr; Amy Harris; Irina Maric; Claudia R Morris; Jung H Suh; James Taylor; Oswaldo Castro; Roberto Machado; Gregory Kato; Mark T Gladwin
Journal:  Eur J Haematol       Date:  2008-02-10       Impact factor: 2.997

10.  Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients.

Authors:  Wendell Vilas-Boas; Bruno A V Cerqueira; Angela M D Zanette; Mitermayer G Reis; Manoel Barral-Netto; Marilda S Goncalves
Journal:  Ann Hematol       Date:  2010-04-20       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.